The research line progressed from tailored doses to controlled release.
Brinter-enabled pharmaceutical research covers personalised dosage forms, dual-release architectures and long-term drug-delivery systems.
Explore evidence →3D-CURE — personalized medicines, controlled drug delivery and digital manufacturing.
A Business Finland research consortium connecting pharmaceutical materials, additive manufacturing, digital twins, process monitoring and regulatory development.
3D-CURE
From formulation to a digital manufacturing route.
3D-CURE brought together research organisations and industrial partners to develop additive manufacturing for personalised medicines and customised drug-delivery devices. The programme addressed the complete manufacturing challenge: printable pharmaceutical materials, multi-component dosage forms, process modelling, quality control and future regulatory requirements.
The consortium was coordinated by Turku University of Applied Sciences and ran from 2023 to 2025 with Business Finland funding.
OUR ROLE
Brinter technology inside pharmaceutical process development.
Brinter Oy participated as an industrial consortium partner, bringing additive-manufacturing platform and extrusion-process expertise into research spanning pharmaceutical formulations, drug-delivery structures and process development.
The project aligns closely with the broader Brinter research record in semi-solid extrusion, tailored dosage forms, dual-release medicines and long-term controlled drug delivery.
FROM RESEARCH TOWARD CONTROLLED PRODUCTION
Materials, process data, quality and regulation developed together.
A central 3D-CURE objective was to move beyond isolated printing experiments toward a more complete production architecture. The work included critical material and process parameters, digital models and digital twins, in-process monitoring, quality attributes and analysis of the regulatory landscape for 3D-printed medicinal products.
That system-level approach reflects the same principle used across BrinterAM's current manufacturing work: product function, process control, validation and future industrialisation need to be considered together from an early stage.
RESEARCH EVIDENCE
Evidence behind the engineering approach.
Doctoral research and project outputs document the manufacturing pathway.
The publication archive includes veterinary dosage-form development, mesoporous-silica drug delivery and multiple semi-solid extrusion studies.
Explore evidence →Explore 3D-CURE.
Read the official project description, objectives, consortium and pharmaceutical manufacturing scope through Turku University of Applied Sciences.
Back to projects →